Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Alprenolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 8/20 | 0.97 |
| ▸ | ADRB1 known ✓ | P08588 | 8/20 | 0.97 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.97 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.97 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.97 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.97 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.97 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.97 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alprenolol SCHEMBL29725600 | 1.00 | LMNA (1.00) | LMNAKDM4EPMP22TDP1ADRB2 | |
| Alprenolol SCHEMBL349102 | 1.00 | LMNA (1.00) | LMNAKDM4EPMP22TDP1ADRB2 | |
| Alprenolol SCHEMBL4538381 | 0.99 | ADRB2 (1.00) | LMNAKDM4EPMP22TDP1ADRB2 | |
| Alprenolol SCHEMBL34636 | 0.99 | ADRB2 (1.00) | LMNAKDM4EPMP22TDP1ADRB2 | |
| Alprenolol SCHEMBL29414120 | 0.99 | ADRB2 (1.00) | LMNAKDM4EPMP22TDP1ADRB2 | |
| Alprenolol SCHEMBL34637 | 0.99 | ADRB2 (1.00) | LMNAKDM4EPMP22TDP1ADRB2 | |
| Alprenolol SCHEMBL29355107 | 0.99 | ADRB2 (1.00) | LMNAKDM4EPMP22TDP1ADRB2 | |
| Alprenolol SCHEMBL6508231 | 0.99 | ADRB2 (1.00) | LMNAKDM4EPMP22TDP1ADRB2 | |
| Alprenolol SCHEMBL10762606 | 0.97 | ADRB2 (0.97) | LMNAKDM4EPMP22TDP1ADRB2 | |
| Alprenolol SCHEMBL7692100 | 0.97 | ADRB2 (0.97) | LMNAKDM4EPMP22TDP1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1637 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023229993-A1 | OPHTHALMIC FORMULATION CAPABLE OF DELIVERING METFORMIN TO CHOROID RPE AND RETINA | CURATIVE BIOTECHNOLOGY, INC. (US) | 2023-11-30 | — | — | WO | claimed |
| US-20230192786-A1 | STAT3 INHIBITION FOR TREATMENT AND PREVENTION OF HUMAN CORONAVIRUS INFECTION | GLG PHARMA LLC (US) | 2023-06-22 | — | — | US | claimed |
| EP-4027985-A1 | DRUGGABLE TARGET TO TREAT RETINAL DEGENERATION | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2022-07-20 | — | — | EP | claimed |
| CN-114650813-A | Druggable targets for the treatment of retinal degeneration | 美国卫生和人力服务部 | 2022-06-21 | — | — | CN | claimed |
| US-20210393597-A1 | TARGETING THE TRANSCRIPTION FACTOR NF-KB WITH HARMINE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-12-23 | — | — | US | claimed |
| WO-2021232067-A1 | STATS3 INHIBITION FOR TREATMENT AND PREVENTION OF HUMAN CORONAVIRUS INFECTION | GLG PHARMA, LLC (US) | 2021-11-18 | — | — | WO | claimed |
| US-20210347847-A1 | THERAPEUTIC TARGETING OF MALIGNANT CELLS USING TUMOR MARKERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2021-11-11 | — | — | US | claimed |
| CN-113117085-A | Medicine and method for preventing and treating alopecia | 中山大学 | 2021-07-16 | — | — | CN | claimed |
| WO-2021050980-A1 | DRUGGABLE TARGET TO TREAT RETINAL DEGENERATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2021-03-18 | — | — | WO | claimed |
| US-20200390786-A1 | COMPOSITIONS AND METHODS FOR TREATING OVARIAN TUMORS | DANA-FARBER CANCER INSTITUTE, INC. | 2020-12-17 | — | — | US | claimed |
| CN-1582168-A | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORP (US) | 2005-02-16 | — | — | CN | claimed |
| EP-0580860-B2 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 2004-12-15 | — | — | EP | claimed |
| EP-1385548-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | Schering Corporation (US) | 2004-02-04 | — | — | EP | claimed |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORPORATION | 2003-04-10 | — | — | US | claimed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| US-5484776-A | REACTION WITH POLYSACCHARIDE | SYNEPOS AKTIENGESELLSCHAFT (LI) | 1996-01-16 | — | — | US | claimed |
| EP-0189861-A2 | Percutaneous absorption accelerator for ionic water-soluble medicine | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1986-08-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390786-A1 | COMPOSITIONS AND METHODS FOR TREATING OVARIAN TUMORS | SLC11A2, BRCA1, RNASE1 | ADRB2 4437/4885ADRB1 4171/4885HTR1A 4701/4885 |
| US-20210347847-A1 | THERAPEUTIC TARGETING OF MALIGNANT CELLS USING TUMOR MARKERS | CD47, CD74, HAVCR2 | ADRB2 4155/4885ADRB1 3972/4885HTR1A 4665/4885 |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | CYP46A1, FABP2, SREBF1 | ADRB2 346/4885ADRB1 193/4885HTR1A 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.